SCHEMBL18901911

SCHEMBL18901911

COC(O)N[C@@H](C(=O)O)C(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.36
CA14 Q9ULX7 1/20 0.36
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.35
ALDH1A1 P00352 2/20 0.34
MMP9 P14780 2/20 0.34
MMP1 P03956 1/20 0.34
MMP2 P08253 1/20 0.34
MMP3 P08254 1/20 0.34
MMP7 P09237 1/20 0.34
MMP8 P22894 1/20 0.34
MMP13 P45452 1/20 0.34
CA2 P00918 4/20 0.33
CA1 P00915 3/20 0.33
NPSR1 Q6W5P4 1/20 0.33
PLA2G2A P14555 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15368155 1.00 CA12 (0.36) CA12CA14TP53SMN1; SMN2LMNA
SCHEMBL15368180 0.80 CA12 (0.38) CA12CA14SMN1; SMN2LMNAGAA
SCHEMBL15898485 0.79 CA12 (0.34) CA12CA14SMN1; SMN2
SCHEMBL21688210 0.78 CTSS (0.34) TP53SMN1; SMN2LMNAGAAHPGD
SCHEMBL23986916 0.78 CTSS (0.34) TP53SMN1; SMN2LMNAGAAHPGD
SCHEMBL22697281 0.77 TP53 (0.43) TP53SMN1; SMN2LMNAGAAHPGD
SCHEMBL19191380 0.75 CA12 (0.35) CA12CA14SMN1; SMN2
SCHEMBL2551696 0.74 ALDH1A1 (0.44) TP53SMN1; SMN2LMNAGAAHPGD
SCHEMBL73645 0.74 ALDH1A1 (0.44) TP53SMN1; SMN2LMNAGAAHPGD
SCHEMBL16750043 0.74 ALDH1A1 (0.44) TP53SMN1; SMN2LMNAGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601188-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-10-18 EP disclosed
EP-2328865-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-05-31 EP disclosed